Every respiratory drug class side by side: quick relief or long-term controller, how it works, what it causes and what to teach. Smoking cessation agents are at the end. No doses.
| Class and drugs | Quick relief or controller | Mechanism | Adverse effects | Cautions and education | Source |
|---|---|---|---|---|---|
| Short-acting beta-2 agonists albuterol (ProAir, Ventolin), levalbuterol (Xopenex) | Quick relief; work rapidly, last 4 to 6 hours | Raise cAMP (cyclic adenosine monophosphate), which inhibits myosin light chain kinase and relaxes airway smooth muscle | Tachycardia, hypotension, headache, dizziness, insomnia, tremor, hyperglycemia | Use sparingly: overuse means poor control; wait 15 to 30 seconds between puffs | L11 slide 70 slide 68 slide 69 slide 71 slide 98 |
| Long-acting beta-2 agonists formoterol (Foradil), salmeterol (Serevent) | Controller; last 12 hours or more | Same as the short-acting drugs (cyclic adenosine monophosphate up, smooth muscle relaxed) | As for the short-acting drugs: increased heart rate, tremor | Never alone for asthma: only with an inhaled corticosteroid | L11 slide 70 slide 68 |
| Inhaled corticosteroids beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone | Controller | Inhibit the inflammatory cascade; lower bronchial responsiveness long term | Oral candidiasis (thrush); growth suppression in children at high dose; immune inhibition (systemic action) | Up to 8 weeks for maximal effect: take daily | L11 slide 73 slide 72 slide 67 |
| Combination inhalers Symbicort, Dulera, Advair | Controller | Formoterol/budesonide (Symbicort), formoterol/mometasone (Dulera), salmeterol/fluticasone (Advair): a long-acting beta-2 agonist plus an inhaled corticosteroid | Those of the two components | The way a long-acting beta-2 agonist is used in asthma | L11 slide 74 |
| Leukotriene modifier montelukast (Singulair) | Controller; oral | Leukotriene D4 receptor (cysteinyl leukotriene 1 receptor) antagonist; that receptor mediates inflammation, bronchial constriction and mucus secretion | Listed as minimal and well tolerated. Current labeling differs: an FDA (Food and Drug Administration) boxed warning for neuropsychiatric events. | Effective in aspirin-induced asthma | L11 slide 75 slide 61 slide 67 |
| Mast cell stabilizers cromolyn sodium, nedocromil (Tilade) | Controller; inhaled; limited use | Stabilize mast cells to remove the trigger or antigen; mechanism unknown (may interfere with calcium) | None listed | Must be taken before the antigen insult; up to 4 weeks to work, so take regularly | L11 slide 78 slide 77 |
| Anti-immunoglobulin E antibody omalizumab (Xolair) | Controller; subcutaneous every 2 to 4 weeks | Binds circulating immunoglobulin E, decreasing high-affinity receptors on mast cells and preventing degranulation | Anaphylaxis, urticaria, gastrointestinal disturbances, neutralizing antibodies, secondary malignancies, injection-site pain, bruising | Watch after each injection | L11 slide 79 slide 80 |
| Other biologics mepolizumab, benralizumab, reslizumab; dupilumab | Controller (step 5 add-on) | Anti-interleukin-5 (mepolizumab, benralizumab, reslizumab; reslizumab given intravenously); anti-interleukin-4 (dupilumab) | Similar to omalizumab | For the eosinophilic phenotype (blood eosinophils above 150 per microliter) | L11 slide 81 slide 90 |
| Methylxanthines theophylline (aminophylline intravenously) | Controller; limited use; used in chronic obstructive pulmonary disease | Inhibits phosphodiesterase (types 4 and 5), raising cyclic adenosine monophosphate and cyclic guanosine monophosphate; adenosine receptor (A2B) antagonist; anti-inflammatory in the late response | Arrhythmias, convulsions, headache, nausea, insomnia, heartburn; gastric acid stimulation; diuresis | Narrow therapeutic index: monitor plasma levels. Less effective and less well tolerated than long-acting bronchodilators. The slides call it renally eliminated; it is mainly metabolized by the liver. | L11 slide 83 slide 82 slide 84 slide 85 |
| Short-acting anticholinergic ipratropium (Atrovent) | Quick relief; up to 8 hours | Blocks acetylcholine at muscarinic receptors: bronchodilation | Anticholinergic: blurry vision, dry mouth and eyes, flushing, fever, constipation, urinary retention, tachycardia, delirium | Teach the dry mouth and urinary retention to report | L11 slide 86 slide 87 slide 67 |
| Long-acting anticholinergic tiotropium (Spiriva) | Controller; 24 hours or more | Same muscarinic block as ipratropium | Same anticholinergic profile | The slides disagree: marked for chronic obstructive pulmonary disease only on the anticholinergic list, yet listed as an add-on at asthma steps 4 and 5. | L11 slide 86 slide 90 |
| Systemic corticosteroids prednisone, prednisolone, methylprednisolone, dexamethasone | Quick relief for exacerbations; intravenous preferred in status asthmaticus | Suppress, control and reverse airway inflammation; inhibit inflammatory cytokines; most potent | Adrenal suppression, growth suppression, dermal thinning, hypertension, hyperglycemia, mood change, steroid myopathy, immunosuppression | Limited use because of side effects; taper a longer course (general rule given: more than 5 days; references differ) | L11 slide 88 slide 89 slide 99 slide 67 |
| Bupropion sustained release Zyban | Smoking cessation | Inhibits norepinephrine and dopamine uptake, mimicking nicotine’s indirect activation of epinephrine and dopamine | — | Avoid with a seizure disorder or monoamine oxidase inhibitors; caution with tricyclic antidepressants and venlafaxine | L11 slide 105 |
| Nicotine replacement patch, gum, spray, inhaler | Smoking cessation; 6 to 12 weeks | Replaces nicotine: reduces craving and physical withdrawal | Tachyarrhythmias, hypertension | Patches and gum are over the counter; caution in cardiovascular disease | L11 slide 106 slide 104 |
| Varenicline Chantix | Smoking cessation; 12 weeks | Partial nicotine receptor agonist, to a lesser degree than nicotine | Nausea, sleep disturbance, headache; black box warning: neuropsychiatric events (depression, suicidal ideation) | Start one week before the quit date. Current labeling differs: the boxed warning was removed in 2016. | L11 slide 107 |